A Comparison of the Efficacy and Safety of Intravenous Followed by Oral Delafloxacin With Vancomycin Plus Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections: A Phase 3, Multinational, Double-Blind, Randomized Study

William O’Riordan,1 Alison McManus,1 Juri Teras,2 Ivan Poromanski,3 Maria Cruz-Saldariagga,4 Megan Quintas,5 Laura Lawrence,5 ShuJui Liang,5 and Sue Cammarata2; for the PROCEED Study Group

1E-study Site, Chula Vista, California; 2North Estonia Medical Centre Foundation, Tallinn; 3Purulent-Septic Surgery Clinic, Multiprofile Hospital Active Treatment and Emergency Medicine, Pirogov EAD, Bulgaria; 4Hospital Nacional Adolfo Guevara Velasco, Cusco, Peru; 5Melinta Therapeutics, Lincolnshire, Illinois; and 6H2O Clinical, Hunt Valley, Maryland

Background. Delafloxacin is an intravenous (IV)/oral anionic fluoroquinolone with activity against gram-positive (including methicillin-resistant Staphylococcus aureus [MRSA]), gram-negative, atypical, and anaerobic organisms. It is approved in the United States for acute bacterial skin and skin structure infections (ABSSSIs) caused by designated susceptible gram-positive and gram-negative organisms, and is in development for the treatment of community-acquired bacterial pneumonia.

Methods. A multicenter, randomized, double-blind trial of 850 adults with ABSSSI compared delafloxacin 300 mg IV every 12 hours for 3 days with a switch to 450 mg oral delafloxacin, to vancomycin 15 mg/kg IV with aztreonam for 5–14 days. The primary endpoint was objective response at 48–72 hours. Investigator-assessed response based on resolution of signs and symptoms at follow-up (day 14 ± 1), and late follow-up (day 21–28) were secondary endpoints.

Results. In the intent-to-treat analysis set, the objective response was 83.7% in the delafloxacin arm and 80.6% in the comparator arm. Investigator-assessed success was similar at follow-up (87.2% vs 84.4%) and late follow-up (83.5% vs 82.2%). Delafloxacin was comparable to vancomycin + aztreonam in eradication of MRSA at 96.0% vs 97.0% at follow-up. Frequency of treatment-emergent adverse events between the groups was similar. Treatment-emergent adverse events leading to study drug discontinuation was higher in the vancomycin + aztreonam group (1.2% vs 2.4%).

Conclusions. In ABSSSI patients, IV/oral delafloxacin monotherapy was noninferior to IV vancomycin + aztreonam combination therapy for both the objective response and the investigator-assessed response at follow-up and late follow-up. Delafloxacin was well tolerated as monotherapy in treatment of ABSSSIs.

Clinical Trials Registration. NCT01984684.

Keywords. delafloxacin; ABSSSI; skin; vancomycin; fluoroquinolone.
against MRSA isolates [11]. This phase 3 study compared the efficacy and safety of intravenous (IV) followed by oral delafloxacin monotherapy to IV vancomycin plus aztreonam combination therapy in adult patients with ABSSSIs caused by either gram-positive or gram-negative pathogens.

**METHODS**

**Trial Design**

This multicenter, multinational, stratified, randomized, double-blind trial enrolled patients at 76 study centers in 16 countries between May 2014 and January 2016. Written informed consent was obtained from each patient and the study protocol was approved by an independent ethics committee or institutional review board at each site. The trial was conducted in accordance with the Declaration of Helsinki and International Conference on Harmonisation Good Clinical Practice.

**Setting and Participants**

Eligibility criteria included age ≥18 years and a diagnosis of ABSSSI defined as cellulitis/erysipelas, wound infection, major cutaneous abscess, or burn infection that was characterized by ≥75 cm² of erythema and ≥2 signs of systemic infection. Patients could receive study drug as inpatients or outpatients, provided that all study drug infusions and oral tablets were administered by blinded study site staff. Complete inclusion and exclusion criteria are presented in the Supplementary Materials.

**Interventions**

Study treatments are summarized in **Table 1**.

Study visits took place at screening, daily until the last day of study drug administration, follow-up (FU [day 14 ± 1]), and late follow-up (LFU [days 21–28]). Telephone follow-up was conducted 30 days following the last dose of study drug to collect 28-day all-cause mortality data, adverse events (AEs), and use of posttreatment medications.

**Outcomes**

The US Food and Drug Administration (FDA)–defined primary efficacy endpoint [12] was the objective response assessment 48–72 hours after initiation of treatment based on ≥20% decrease in lesion size assessed by digital planimetry of the leading edge in the absence of clinical failure. The definition of clinical failure was (1) <20% reduction of the ABSSSI lesion spread of erythema area; (2) administration of rescue antibacterial drug therapy or administration of nonstudy antibacterial drug therapy for treatment of the ABSSSI before the primary efficacy endpoint assessment; (3) unplanned surgical intervention excluding limited bedside debridement and standard wound care before the primary efficacy endpoint assessment; or (4) death within 72 hours after initiation of study drug. If digital planimetry was not available within the 48- to 72-hour window, patients were classified as missing and clinical failures in the intent-to-treat (ITT) analysis.

**Table 1. Study Treatments and Blinding Strategy**

| Treatment Arm | CrCl at Screening | Dose | Method of Administration | Blinding Strategy |
|---------------|-------------------|------|--------------------------|-------------------|
| Delafloxacin  >29 mL/min | 300 mg IV, Q12h | Patients received delafloxacin over a 1-h infusion Q12h for 6 doses with mandatory switch to oral delafloxacin for all remaining doses. | Blinded placebo infusion was given in place of aztreonam, which was discontinued if a gram-negative organism was not identified in baseline culture. |
| | 450 mg orally, Q12h | Administered as a single tablet with 8 oz of water. | IV placebo was continued BID to maintain blinding. |
| | 15–29 mL/min | 200 mg IV, Q12h | Patients received IV delafloxacin 200 mg over a 1-h infusion Q12h for all doses. | Blinded placebo infusion was given in place of aztreonam, which was discontinued if a gram-negative organism was not identified in baseline culture. |
| Vancomycin + aztreonam >29 mL/min | Vancomycin 15 mg/kg Q12h | Vancomycin dosing was based on actual body weight with a target trough concentration of >15–20 μg/mL. It was recommended that study sites monitor vancomycin therapeutic drug levels on day 2 and day 6. | All sites had to have an approved vancomycin blinding plan with vancomycin dosing managed by designated unblinded personnel. |
| | Aztreonam 2 g Q12h | Administered as a 30-min infusion until baseline cultures were confirmed negative for gram-negative pathogens. | After the first 6 doses, patients randomized to vancomycin also received oral placebo BID to maintain blinding. |
| | 15–29 mL/min | Vancomycin | Renal adjustment for vancomycin patients was allowed and was part of an approved vancomycin dosing plan for each site to maintain trough target. |
| | Aztreonam 1 g Q12h | Administered as a 30-min infusion until baseline cultures were confirmed negative for gram-negative pathogens. |

Abbreviations: BID, twice daily; CrCl, creatinine clearance; IV, intravenous; Q12h, every 12 hours.
The European Medicines Agency (EMA)–defined primary efficacy measure [13] was the investigator assessment of clinical response at the FU visit in the ITT population, defined as all randomized patients. Clinical response was based on ABSSSI signs and symptoms and was categorized as cure (complete resolution); improved (some symptoms but no additional need for antibiotics); failure (additional nonstudy antibiotics required); or indeterminate (incomplete assessment). Patients with missing follow-up data and those with improved outcomes were combined with failures in the primary ITT analysis. An additional secondary endpoint was investigator-assessed success (cure plus improved and no further antibiotic needed) at the FU visit. Other antibiotic studies in skin infections have defined a successful outcome as resolution or near resolution of signs and symptoms that no longer require antibiotic therapy. This definition aligns with the definition of success in this study.

Patients’ subjective assessment of pain was recorded on a numerical rating scale ranging from 0 (no pain) to 10 (pain as bad as imaginable) at baseline, during treatment, and at end of therapy (EOT), FU, and LFU.

Microbiological Assessments
Microbiological response was categorized as documented eradicated (baseline pathogen absent in follow-up cultures); presumed eradicated (no follow-up material available for culture, but the patient had a clinical response of success); documented persisted (baseline pathogen present in follow-up cultures); or presumed persisted (no follow-up material available for culture, but the patient had a clinical response of failure).

Safety and Tolerability Assessments
Safety assessments included all AEs, physical examinations, vital sign measurements, 12-lead electrocardiograms at baseline and as clinically indicated thereafter, and clinical laboratory tests. Patients were contacted by telephone 30 days after the final dose of study drug to assess the occurrence of long-term AEs. Treatment-emergent adverse events (TEAEs) were defined as events that occurred or worsened following administration of the first dose of the study drug through the 30-day telephone follow-up.

Randomization and Blinding
Patients were randomized (1:1), with randomization stratified by infection category and baseline body mass index (BMI). Infection categories were limited to ≤25% of patients with a major cutaneous abscess and ≤30% with wound infections. Patients were characterized by BMI as <30 kg/m² and ≥30 kg/m² (obese); patients with a BMI ≥30 kg/m² were limited to no more than 50% of enrolled patients.

Statistical Methods
Separate statistical analysis plans for the FDA and the EMA were prospectively developed prior to database lock and unblinding. Clinical efficacy outcomes were analyzed for the ITT population while the safety analysis population included all enrolled patients administered at least 1 dose of study drug. Analysis of microbiological outcomes was based on the microbiological intent-to-treat (MITT) population. There were multiple microbiologically evaluable (ME) and clinically evaluable (CE) analysis sets, each based on the type of assessment (investigator-assessed or objective) and timing of the assessment (48–72 hours, EOT, FU, LFU).

Descriptive statistics (mean, median, minimum, and maximum) described continuous variables while counts and percent-ages were calculated for categorical data. The rate of the primary FDA-defined efficacy endpoint was the sample responder rate defined as (responder / [responder + nonresponder]). The rate of the primary EMA-defined efficacy endpoint was the sample cure rate defined as (cure / [cure + failure]).

A 2-sided 95% confidence interval (CI) for noninferiority testing was computed based on the difference in sample responder rates and investigator-assessed response rates for vancomycin/aztreonam and delafloxacin at 48–72 hours following initiation of treatment using a nonstratified method [14]. Noninferiority was concluded if the lower limit of the 2-sided 95% CI exceeded –10%. Mean differences between treatments were expressed as delafloxacin minus vancomycin/aztreonam.

All analyses were performed with SAS software version 9.2 or higher (SAS Institute, Cary, North Carolina).

RESULTS
Patient Disposition and Analysis Sets
Eight hundred fifty patients were randomized (ITT population), including 423 to delafloxacin and 427 to vancomycin/aztreonam (Figure 1). Overall, 766 (90.1%) enrolled patients completed the study through the FU visit. A total of 842 randomized patients received at least 1 dose of study drug (safety population), and 552 patients had an identified baseline pathogen known to cause ABSSSIs (MITT population).

Baseline Characteristics
Baseline characteristics were similar between treatment groups (Table 2). Overall, 46.8% of patients were from North America with an additional 39.8% from Europe; 23.5% received antibacterial therapy in the 14 days prior to enrollment. ABSSSI categories were similarly distributed between the treatment groups (Table 3).

Among the 839 patients with an ABSSSI culture at baseline, S. aureus was the most frequently identified organism in 58.2% of isolates in the delafloxacin group and 57.0% of isolates in vancomycin/aztreonam patients. MRSA was detected in 24.0% and 18.1%, respectively (Table 3). Delafloxacin minimum inhibitory concentration (MIC)90/95 was 0.008/0.25 µg/mL (range, 0.002–4 µg/mL) for S. aureus, 0.12/0.25 µg/mL (range, 0.002–4 µg/mL) for MRSA, and 0.008/0.008 µg/mL (range, 0.002–0.12 µg/mL) for methicillin-susceptible S. aureus (MSSA). Overall, 96% of MRSA isolates were susceptible to delafloxacin (delafloxacin MIC ≤0.25 µg/mL).
Approximately 26% of *S. aureus* isolates were levofloxacin nonsusceptible (delafloxacin MIC range, 0.012–4 µg/mL); of these, 93% of levofloxacin-nonsusceptible *S. aureus* isolates were susceptible to delafloxacin; the majority were also MRSA. Gram-negative pathogens were identified in 20.7% (114/552) of patients with pathogens at baseline. Overall, 19 (2.2%) patients had bacteremia at baseline.

### Clinical Outcomes

#### Objective Response

The percentage of patients classified as responders in the ITT analysis population at 48–72 hours after initiation of study drug was similar between the 2 groups at 83.7% and 80.6% for delafloxacin and vancomycin/aztreonam, respectively. The difference in responder rates was 3.1% (95% CI, −2.0% to 8.3%; [Figure 2](#)), demonstrating noninferiority of delafloxacin compared to vancomycin/aztreonam. Equivalent efficacy for delafloxacin was also demonstrated for the CE, ME, and MITT analyses. The percentage reduction from baseline in digital measurements of erythema was similar between the 2 groups at each visit (48–72 hours; EOT; FU; LFU) in the ITT analysis group.

#### Investigator-Assessed Response

The primary efficacy endpoint for the EMA submission and a secondary efficacy endpoint for the FDA submission was the investigator-assessed response of signs and symptoms of infection at FU in the ITT population. The cure rate of 57.7% for the delafloxacin group was noninferior to the rate of 59.7% observed in the vancomycin/aztreonam group with a difference of −2.0% (95% CI, −8.6 to 4.6). Noninferiority of delafloxacin compared to vancomycin/aztreonam was also confirmed for the MITT, CE, and ME analysis sets ([Figure 2](#)).

A sensitivity analysis in which success was defined as cure plus improved and failure as indeterminate plus failure revealed similar success rates between the 2 groups in the ITT analysis set (87.2% and 84.8% [difference, 2.5%; 95% CI, −2.2% to 7.2%]).

---

**Figure 1.** Consolidated Standards of Reporting Trials (CONSORT) diagram of patient disposition. Intent-to-treat (ITT) analysis set included all patients who were randomly assigned to treatment. Clinically evaluable (CE) analysis set included all patients in the ITT population who (1) received ≥80% of the total expected doses of the assigned study drug or experienced clinical failure and received ≥4 doses of study drug; (2) did not receive any concomitant, systemic antibacterial therapy with activity against the identified pathogen; and (3) had no major protocol deviations. Microbiological ITT (MITT) analysis set consisted of all patients in the ITT analysis set who had bacterial pathogens known to cause acute bacterial skin and skin structure infections at baseline. Microbiologically evaluable analysis set included all patients in the MITT population who met the criteria established for the CE analysis set. Abbreviations: AE, adverse event; CE, clinically evaluable; FU, follow-up; ITT, intent-to-treat; LFU, late follow-up; ME, microbiologically evaluable; MITT, microbiological intent-to-treat; SAF, safety; TC, telephone call.
for the delafloxacin and vancomycin/aztreonam groups) as well as for the CE, MITT, and ME analysis sets (Figure 2).

In patients with bacteremia, 8 of 11 (72.7%) delafloxacin-treated patients and 5 of 8 (62.5%) vancomycin/aztreonam-treated patients had successful outcomes (investigator assessment of success, ITT). This included 1 patient with *Pseudomonas aeruginosa* bacteremia who was a clinical success in the delafloxacin arm. The mean baseline patient-reported pain score was 7.4 and 7.2 for delafloxacin and vancomycin, respectively. In the ITT analysis set, mean pain scores were similar between the delafloxacin and vancomycin/aztreonam groups at the FU assessment at 0.5 and 0.6, respectively. Mean pain scores were the same for both groups at 1.2 and 0.3 for EOT and LFU, respectively.

### Microbiological Efficacy

Overall pathogen eradication rates were similar between the delafloxacin group at 97.8% and 97.6% for the vancomycin/aztreonam group, with a difference of 0.2% (95% CI, −2.9% to 3.5%).

The most common pathogen was *S. aureus*; rates of microbiological success approached 100.0% in both groups at FU. Per-pathogen early objective response at 48–72 hours and microbiological response rates were similar between the 2 treatment groups Tables 4 and 5. The microbiological response was similar for patients with MRSA infections at 96.0% and 97.0% for delafloxacin and vancomycin/aztreonam, respectively. Additionally, there was 97% documented or presumed eradication for the levofloxacin-nonsusceptible *S. aureus* isolates in the delafloxacin group. No isolates were shown to have an increase in delafloxacin MIC values during the course of therapy; emergence of resistance was not seen.

### Safety

In the safety analysis set, 43.6% of those administered delafloxacin and 39.3% of the vancomycin/aztreonam group reported 1 or more TEAEs, and the percentage of TEAEs considered related

---

**Table 2.** Patient Baseline Demographic and Clinical Characteristics: Intent-to-Treat Population

| Characteristic                                      | Delafloxacin (n = 423) | Vancomycin + Aztreonam (n = 427) | Overall (N = 850) |
|-----------------------------------------------------|-------------------------|----------------------------------|-------------------|
| Age, y, mean ± SD (range)                           | 51.2 ± 15.98 (18–89)    | 50.2 ± 16.03 (19–93)             | 50.7 ± 16.00 (18–93) |
| Age category, y, No. (%)                            |                         |                                  |                   |
| ≤65                                                 | 344 (81.3)              | 352 (82.4)                       | 696 (81.9)        |
| 65–75                                               | 79 (18.7)               | 75 (17.6)                        | 154 (18.1)        |
| >75                                                 | 35 (8.3)                | 31 (7.3)                         | 66 (7.8)          |
| Male sex, No. (%)                                   | 262 (61.9)              | 276 (64.6)                       | 538 (63.3)        |
| Race, No. (%)                                       |                         |                                  |                   |
| White                                               | 348 (82.3)              | 356 (83.1)                       | 703 (82.7)        |
| Black/African American                              | 13 (3.1)                | 18 (4.2)                         | 31 (3.6)          |
| American Indian/Alaska Native                       | 12 (2.8)                | 7 (1.6)                          | 19 (2.2)          |
| Asian                                               | 11 (2.6)                | 15 (3.5)                         | 26 (3.1)          |
| Native Hawaiian/Other Pacific Islander              | 2 (0.5)                 | 2 (0.5)                          | 4 (0.5)           |
| Other                                               | 37 (8.7)                | 30 (7.0)                         | 67 (7.9)          |
| Ethnicity, No. (%)                                  |                         |                                  |                   |
| Hispanic or Latino                                  | 132 (31.2)              | 99 (23.2)                        | 231 (27.2)        |
| Region, No. (%)                                     |                         |                                  |                   |
| Europe                                              | 165 (39.0)              | 173 (40.5)                       | 338 (39.8)        |
| North America                                       | 202 (47.8)              | 196 (45.9)                       | 398 (46.8)        |
| Asia                                                | 9 (2.1)                 | 14 (3.3)                         | 23 (2.7)          |
| Latin America                                       | 47 (11.1)               | 44 (10.3)                        | 91 (10.7)         |
| BMI, kg/m², mean ± SD                               | 30.4 ± 7.44             | 30.7 ± 7.54                      | 30.5 ± 7.49       |
| ≤30                                                 | 211 (49.9)              | 214 (50.1)                       | 425 (50.0)        |
| Diabetes, No. (%)                                   | 53 (12.5)               | 54 (12.6)                        | 107 (12.6)        |
| Prior antibiotic use, No. (%)                       | 89 (21.0)               | 111 (26.0)                       | 200 (23.5)        |
| Baseline pain score, mean ± SD                      | 74 ± 2.30               | 72 ± 2.40                        |                   |
| Medical history relevant to substance abuse         | 129 (30.5)              | 125 (29.3)                       |                   |
| including IVDA, No. (%)                             |                         |                                  |                   |
| Duration of exposure, d                             |                         | 417                               | 425               |
| No.                                                 |                         | 73 ± 2.97                        | 70 ± 2.92         |
| Mean ± SD                                          |                         | 6.5                              | 6.5               |
| Min, Max                                           |                         | 0.5, 14.0                        | 0.5, 14.5         |

Abbreviations: BMI, body mass index; IVDA, intravenous drug abuse; SD, standard deviation.

*Medical history was coded using the Medical Dictionary for Regulatory Activities version 16.1. At each level of summarization, a subject was counted once if the subject reported 1 or more events. Preferred terms used: drug dependence, drug abuse, substance use, drug abuser, substance abuse, and substance abuser.
to study drug was comparable between the 2 groups (Table 6). The percentages of TEAEs resulting in early discontinuation of study drug and serious AEs were similar between treatment groups. Most TEAEs were considered to be mild in severity in both treatment groups, with 30 patients experiencing ≥1 severe TEAE, including 16 (3.8%) patients in the delafloxacin group and 14 (3.3%) patients in the vancomycin/aztreonam group. Two deaths occurred in the vancomycin/aztreonam group and none in the delafloxacin arm; both deaths were considered not related to treatment. One (0.2%) patient treated with delafloxacin developed *Clostridium difficile* diarrhea (prior treatment failure on trimethoprim/sulfamethoxazole and clindamycin), with no cases reported in the vancomycin/aztreonam arm. There were no cases of tendinitis, tendon rupture, or myopathy and 1 case of paresthesia in each treatment group that was thought to be potentially related to treatment. There were no reports of treatment-related hypo- or hyperglycemia during trial in either group.

There were no significant differences between the 2 treatments in changes from baseline in hematology and/or chemistry parameters. There were no increases in hepatic AEs in the delafloxacin treatment group when compared to vancomycin/aztreonam. A lower percentage of patients in the delafloxacin group compared with the vancomycin/aztreonam group had an alanine aminotransferase value at least once postbaseline that was >5 times the upper limit of normal (ULN) (1.2% [5/417] delafloxacin vs 1.9% [8/425] vancomycin/aztreonam). Only 4 and 2 patients in delafloxacin and vancomycin/aztreonam groups, respectively, had aspartate aminotransferase >5 times the ULN at any time during the trial. No patient in either treatment group met potential Hy's law criteria. Serum creatinine >2 times the ULN was seen in 7 vancomycin-treated patients at any time during the trial, compared to no reports in delafloxacin patients.

DISCUSSION

This phase 3 trial of IV followed by oral delafloxacin showed that in patients with ABSSSI, IV/oral delafloxacin monotherapy was noninferior to IV vancomycin/aztreonam combination therapy. The addition of oral delafloxacin appears to maintain the initial clinical response seen with IV delafloxacin providing an option of switching from IV to oral therapy as soon as patients are clinically stable.
Delafloxacin patients had comparable per-pathogen microbiological response rates vs vancomycin/aztreonam patients against important pathogens that cause ABSSSIs, including MRSA and gram-negative bacteria. The eradication rate in patients with MSSA was higher in the delafloxacin group compared with the vancomycin/aztreonam group. Although the numbers were small, IV/oral delafloxacin monotherapy had eradication rates of 100% for gram-negative pathogens such as Escherichia coli, P. aeruginosa, and Klebsiella pneumoniae, which included isolates from monomicrobial infections.

Emergence of resistance was not seen in the study. In a resistance selection study, delafloxacin demonstrated a low probability for the selection of resistant mutants in MRSA [15, 16]. In addition, analysis of phase 3 data shows high eradication of fluoroquinolone-nonsusceptible isolates.

Delafloxacin appeared to be well tolerated in this study with a lower rate of discontinuation due to related TEAEs than vancomycin/aztreonam: 5 of 417 (1.2%) and 10 of 425 (2.4%), respectively. Previous studies have documented that delafloxacin was not associated with QT prolongation [17] or phototoxicity [18], and has minimal potential for drug interactions [19].

Similar results were seen in a recently published phase 3 study of 660 patients that compared delafloxacin 300 mg or vancomycin 15 mg/kg plus aztreonam 2 g each administered twice daily intravenously for 5–14 days in the treatment of ABSSSIs. Delafloxacin was found to have comparable clinical activity to vancomycin and was well tolerated [20].

While gram-positive pathogens are the most common bacteria identified in ABSSSI, gram-negative pathogens are increasing in prevalence and must be considered when selecting initial empiric therapy [3]. A large prospective observational study found that nearly 25% of patients hospitalized for cSSTIs received initial inappropriate therapy, a finding similar to those in other studies [8, 21–25]. The most common independent risk factors of initial inappropriate therapy was shown to be infection that included gram-negative pathogens. Clinicians must...
be attuned to specific patient risk factors which lead to consideration of gram-negative coverage [3, 9, 25]. The current FDA definition of ABSSSI used in this study excludes patients with infection types including diabetic foot infection, osteomyelitis, and decubitus ulcer from ABSSSI studies and limits the ability to investigate patients with gram-negative infections. Even given this study limitation, 20.7% of patients in this study had a gram-negative pathogen identified. Though further study in patients most likely to have a gram-negative infection would be important, delafloxacin may offer a monotherapy option for the treatment of ABSSSI in these patient types.

Because in previous studies a signal was seen indicating that delafloxacin may provide benefit in obese patients, this study randomized and was stratified for obesity [20, 26]. Rates of cure and success in obese patients were similar between the delafloxacin and vancomycin/aztreonam groups. Delafloxacin administered at the standard dose of 300 mg every 12 hours IV and oral delafloxacin 450 mg every 12 hours was found to provide good outcomes in obese patients (BMI ≥30 kg/m²), potentially simplifying dosing in this patient population. Due to limitations on vancomycin dosing and infusion time and thus blinding, patient weight was limited to a maximum of 200 kg.

Additional limitations to this study include a low number of burn and surgical wounds, and relative to the general population, the number of older adults and nonwhites was lower.

Patients in this study were enrolled based upon the most recent FDA guidance for industry for the study of drugs for the treatment of ABSSSI. This guidance was developed to support an indication for the treatment of ABSSSI and exclude less serious skin infections such as impetigo and minor cutaneous abscess [27]. Use of this guidance has made results of more recent trials more consistent by defining infection types and size of lesions that should be included as well as exclusion criteria.

Extensive use of fluoroquinolones has led to recognition of a variety of rare AEs and acknowledgement that the class should be used more appropriately as noted in FDA guidance [28]. Delafloxacin product labeling includes these risks associated with the fluoroquinolones. Based on currently available data, delafloxacin does not appear to be associated with an increased risk of AEs associated with other fluoroquinolones [29]. Future observation as the drug is more widely used in the clinic will be prudent.

In this study, in ABSSSI patients, IV/oral delafloxacin monotherapy was noninferior to IV vancomycin/aztreonam combination therapy for both the objective and the investigator-assessed response rates and was well tolerated. With both an IV and oral formulation, delafloxacin offers a potential treatment option for ABSSSI due to gram-positive (including MRSA) and gram-negative bacteria.
Table 6. Overall Summary of Adverse Events and Treatment-Emergent Adverse Events: Safety Population

| Adverse Event                                                                 | Delafloxacin (n = 417) | Vancomycin + Aztreonam (n = 425) |
|-------------------------------------------------------------------------------|-------------------------|----------------------------------|
| Any TEAE regardless of causality affecting ≥2% of patients                    | 182 (43.6)              | 167 (39.3)                       |
| Nausea                                                                        | 32 (7.7)                | 19 (4.5)                         |
| Diarrhea                                                                      | 32 (7.7)                | 14 (3.3)                         |
| Infection                                                                     | 16 (3.8)                | 15 (3.5)                         |
| Headache                                                                      | 14 (3.4)                | 16 (3.8)                         |
| Infusion site extravasation                                                   | 13 (3.1)                | 10 (2.4)                         |
| Pyrexia                                                                       | 11 (2.6)                | 9 (2.1)                          |
| Vomiting                                                                      | 10 (2.4)                | 8 (1.9)                          |
| Increase in creatinine phosphokinase                                          | 5 (1.2)                 | 10 (2.4)                         |
| Pruritus                                                                       | 4 (1.0)                 | 9 (2.1)                          |
| TEAE related to study drug                                                    | 87 (20.9)               | 89 (20.9)                        |
| TEAE of moderate or severe intensity                                          | 75 (18.0)               | 86 (20.2)                        |
| Any TEAE resulting in premature study drug discontinuation                    | 10 (2.4)                | 12 (2.8)                         |
| Any related TEAE resulting in premature study drug discontinuation            | 5 (1.2)                 | 10 (2.4)                         |
| Any SAE                                                                       | 16 (3.8)                | 17 (4.0)                         |
| Deaths                                                                        | 0. (0.0)                | 2 (0.5)                          |

Data are presented as No. (%).

Abbreviations: SAE, serious adverse event; TEAE, treatment-emergent adverse event.

Supplementary Data

Supplementary materials are available at Clinical Infectious Diseases online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyrighted and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

Notes

Acknowledgments. All authors participated in the execution and completion of the study and drafting and review of this manuscript. E. S., L. L., and S. C. were responsible for development of the protocol. S. L. provided statistical and analytic support. We thank the members of the PROCEED Study Group who enrolled patients in the study.

Financial support. This study was funded by Melinta Therapeutics. Editorial assistance for this manuscript was provided by Strategic Healthcare Communications, Hillisborough, New Jersey, funded by Melinta Therapeutics.

Potential conflicts of interest. W. O., A. M., J. T., I. P., and M. C.-S. were provided research support by Melinta Therapeutics. M. Q., L. L., and S. C. are employed by Melinta Therapeutics. S. L. is employed by H2O Clinical, which was paid to provide statistical and analytic support. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

1. Garau J, Biasi E, Medina J, McBride K, Ostermann H; REACH Study Group. Early response to antibiotic treatment in European patients hospitalized with complicated skin and soft tissue infections: analysis of the REACH study. BMC Infect Dis 2015; 15:78.
2. Ektare V, Khachatryan A, Xue M, Dunne M, Johnson K, Stephens J. Assessing the economic value of avoiding hospital admissions by shifting the management of gram + acute bacterial skin and skin-structure infections to an outpatient care setting. J Med Econ 2015; 18:1092–101.
3. Guillamet CV, Kollef MH. How to stratify patients at risk for resistant bugs in skin and soft tissue infections? Curr Opin Infect Dis 2016; 29:116–23.
4. Lipsky BA, Napolitano LM, Moran GJ, et al. Economic outcomes of inappropriate initial antibiotic treatment for complicated skin and soft tissue infections: a multicenter prospective observational study. Diagn Microbiol Infect Dis 2014; 79:266–72.
5. Russo A, Concia E, Cristini E, et al. Current and future trends in antibiotic therapy of acute bacterial skin and skin-structure infections. Clin Microbiol Infect 2016; 22(Suppl 2):S27–36.
6. Itani KM, Merchant S, Lin SJ, Akiras K, Alamet JC, Hatoum HT. Outcomes and management costs in patients hospitalized for skin and skin-structure infections. Am J Infect Control 2011; 39:42–9.
7. Berger A, Oster G, Ekelberg J, Huang X, Weber DJ. Initial treatment failure in patients with complicated skin and skin structure infections. Surg Infect (Larchmt) 2013; 14:304–12.
8. Ekelberg J, Taneja C, Zervos M, et al. Trends in US hospital admissions for skin and soft tissue infections. Emerg Infect Dis 2009; 15:1516–8.
9. Hallilovic J, Heinitz BH, Brown J. Risk factors for clinical failure in patients hospitalized with cellulitis and cutaneous abscesses. J Infect 2012; 65:128–34.
10. Van Bambeke F. Delafloxacin, a non-swissertonic fluoroquinolone in phase III of clinical development: evaluation of its pharmacology, pharmacokinetics, pharmacodynamics and clinical efficacy. Future Microbiol 2015; 10:1111–23.
11. McCurdy S, Lawrence L, Quintas M, et al. In vitro activity of delafloxacin and microbiological response against fluoroquinolone susceptible and non-susceptible S. aureus isolates from two phase 3 studies of acute bacterial skin and skin structure infections (ABSSS1). Antimicrob Agents Chemother 2017; 61. doi:10.1128/AAC.00772-17.
12. Center for Drug Evaluation and Research (CDER). Guidance for industry. acute bacterial skin and skin structure infections: developing drugs for treatment. 2013. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM071185.pdf
Accessed 18 March 2018.
13. European Medicines Agency (EMA). Committee for Medicinal Products for Human Use (CHMP). Guideline on the evaluation of medicinal products indicated for treatment of bacterial infections. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/03/WC500079928.pdf
Accessed 18 March 2018.
14. Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med 1985; 4:213–26.
15. Remy JM, Tow-Keogh CA, McConnell TS, Dalton JN, Devito JA. Activity of delafloxacin against methicillin-resistant Staphylococcus aureus: resistance selection and characterization. J Antimicrob Chemother 2012; 67:2814–20.
16. McCurdy S, Lawrence L, Quintas M, et al. In vitro activity of delafloxacin and microbiological response against fluoroquinolone susceptible and non-susceptible S. aureus isolates from two phase 3 studies of acute bacterial skin and skin structure infections (ABSSS1). Antimicrob Agents Chemother 2017; 61:60772–17.
17. Litwin JS, Benedict MS, Thorn MD, Lawrence LE, Cammarata SK, Sun E. A thorough QT study to evaluate the effects of therapeutic and supratherapeutic doses of delafloxacin on cardiac repolarization. Antimicrob Agents Chemother 2015; 59:3469–73.
18. Ferguson J, Lawrence L, Paulson S, et al. Assessment of phototoxicity potential of delafloxacin in healthy male and female subjects: a phase 1 study [abstract F-1198a]. In: 55th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 17–21 September 2015.
APPENDIX

PROCEED Study Group. Gustavo Jorge Chaparro, Sr – Buenos Aires, Argentina; Natalia Elizabeth Frassone – Córdoba, Argentina; Graciela Morera – Santa Fe, Argentina; Antonio Tarcisio de Faria Freire, Sr – Minas Gerais, Brazil; Júlio César Stobbe – Rio Grande do Sul, Brazil; Rosenn Stoyanov Dimov – Plovdiv, Bulgaria; Borislav Tzvetanov Ninov, Sr – Pleven, Bulgaria; Ivan Poromanski – Sofia, Bulgaria; Petar Rusev – Plovdiv, Bulgaria; Simeon Simeonov – Ruse, Bulgaria; Georgi Vasilev Todorov – Sofia, Bulgaria; Jorge Manuel Perez Rusev – Plovdiv, Bulgaria; Rossen Stoyanov Tarcisio de Faria Freire, Sr – Minas Gerais, Brazil; Júlio Argentina; Graciana Morera – Santa Fe, Argentina; Antonio Buenos Aires, Argentina; Melanie Hoppers – Jackson, Tennessee.

Foreign Members:

- Gabriel Gabriel – Cluj-Napoca, Romania; Petrisor Z. Crainiceanu – Banska Bystrica, Slovakia; Y en-Hsu Chen – Kaohsiung, Taiwan; Yin-Shih Yeh – Taipei, Taiwan; Lajos Kemény – Szeged, Hungary; Levente Katalin Egyud – Nyiregyhaza, Hungary; Zsolt Horváth – Kecskemét, Hungary; Lajos Kemény – Szeged, Hungary; Levente Kövágó – Veszprém, Hungary; Tibor Olah – Kaposvar, Hungary; Yong Kyun Cho, Sr – Incheon, Republic of Korea; Seong-Ho Choi – Seoul, Republic of Korea; Won Seok Choi – Ansan Republic of Korea; Yong Pill Chong – Seoul, Republic of Korea; Min Ja Kim – Seoul, Republic of Korea; Shin-Woo Kim – Daegu, Republic of Korea; Yeon Sook Kim, Sr – Daejeon, Republic of Korea; Janis Gardovskis – Riga, Latvia; Viktors Lovcinovskis – Daugavpils, Latvia; Mari Sali – Liepaja, Latvia; Guntars Pupelis – Riga, Latvia; Eduardo Rodriguez Noriega – Guadalajara, Mexico; Nora Patricia Quintero Pérez – Guadalajara, Mexico; Adrian Camacho Ortiz – Monterrey, Mexico; Eugen Gutu – Chisinau, Republic of Moldova; Sergiu Revenu – Chisinau, Republic of Moldova; Sergiu Ungureanu – Chisinau, Republic of Moldova; Luis A Camacho Cosavalle – Trujillo, Peru; Jaime Ismael Soria Medina – Lima, Peru; Maria Edelmira Cruz – Cusco, Peru; Oscar Guillermo Pamo Reyna – Lima, Peru; Pedro Esteban Legua Leiva – Lima, Peru; Marius Eugen Ciurea – Craiova, Romania; Ion Florea – Craiova, Romania; Carmen Giuglea – Bucharest, Romania; Silviu Adrian Marinescu – Bucharest, Romania; Silviu Horia Morarui – Targu Mures, Romania; Remus Ioan Orasan – Cluj-Napoca, Romania; Petrisor Z. Crainiceanu – Banska Bystrica, Slovakia; Yen-Hsue Chen – Kaohsiung, Taiwan; Yin-Ching Chuang – Tainan City, Taiwan; Sinikka Liisa Green – La Mesa, California; Alison J. McManus – Chula Vista, California; Jeffrey K. Kingsley – Columbus, Georgia; Loren Miller – Torrance, California; Robert Houghton – San Diego, California; Verne Leroy Willits – Channelview, Texas; Steven Hugh Mannis – Oceanside, California; Sheri Stucke – Las Vegas, Nevada; Peter Rives – Savannah, Georgia; Eric Hansen – Somers Point, New Jersey; Pietro Giuseppe Pecci – Modesto, California; Hermilito L. Villar, Anaheim, California; Richard Beasley – Rapid City, South Dakota; Philip A. Giordano – Orlando, Florida; John Pullman – Mutte, Montana; Chok Ping Wan – Long Beach, California; Shaukat Shah – Stockton, California; Godson I. Oguchi – Deland, Florida; Thomas M. Birch – Teaneck, New Jersey; Sadi M. Dar – Smyrna, Tennessee; Barr L. Baynton – San Antonio, Texas; Melanie Hoppers – Jackson, Tennessee.